A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of LY01610 (an Irinotecan Hydrochloride Liposome Injection) as a Second-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC)
crossref（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要